Back to search
FDAFDA · Food and drugs·Recall number D-1449-2016

Divalproex Sodium Delayed-release Tablets USP, RX, 250 mg, 100 count bottles, Manufactured in Israel by: TEVA PHARMACEUTICALS IND. LTD. Jerusalem, 9777402, Israel, Manufactured for: TEVA PHARMACEUTICALS USA, INC. North Wales, PA 19454, NDC 0093-7440-01.

Published August 3, 2016 · Recall initiated: May 18, 2016

Summary

FDA records drug Class III recall D-1449-2016, published August 3, 2016 and initiated May 18, 2016. Recalling firm: Teva North America; Status: Terminated; Reported quantity: 14, 370 units; Lot: Lot #: 02D163, Exp. 9/2017. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Tablet/Capsule Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva North America
Distributor
Nationwide and Puerto Rico
Lot
Lot #: 02D163, Exp. 9/2017
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Divalproex Sodium Delayed-release Tablets USP, RX, 250 mg, 100 count bottles, Manufactured in Israel by: TEVA PHARMACEUTICALS IND. LTD. Jerusalem, 9777402, Israel, Manufactured for: TEVA PHARMACEUTICALS USA, INC. North Wales, PA 19454, NDC 0093-7440-01. recalled?

Yes. FDA published recall D-1449-2016 on August 3, 2016. Reported hazard: Failed Tablet/Capsule Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter